Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...
Stockhead on MSN
Health Check: Telix jumps first hurdle with its advanced prostate cancer therapy trial
In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ... Read More The post Health Check: Telix jumps first hurdle with its ...
Having survived the cancer which took his father, Graham Heron, from Bovington, is urging more men to act quickly to avoid falling victim to the most common cancer affecting men in the UK.
FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, ...
Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial ...
The MarketWatch News Department was not involved in the creation of this content. Neuroendocrine Carcinoma Market Poised for Significant Growth During the Forecast Period (2026-2036) Driven by Rising ...
Good morning, everybody. My name is Kyahn Williamson, SVP of Investor Relations and Corporate Communications at Telix. And we're very pleased to welcome you today to our investor call and webcast to ...
New research suggests that a vegetarian diet can help lower the risk of cancer, but not in all cases. We spoke to experts to ...
The neuroendocrine carcinoma market is experiencing steady growth driven by rising disease prevalence and improved diagnostic capabilities. Advancements in targeted therapies and immunotherapies ...
Telix Pharmaceuticals reports positive Phase 3 safety results for its investigational prostate cancer therapy, TLX591-Tx. The post Telix Pharmaceuticals reports positive TLX591-Tx Phase 3 results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results